| Segment | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| VOXZOGO | $189.79M | $208.5M | $213.75M | $221.39M | $218.39M | $273.39M | $219.88M | $252.53M |
| VIMIZIM | $178.16M | $191.09M | $188.35M | $215.42M | $182.76M | $205.53M | $210.2M | $194.37M |
| NAGLAZYME | $131.91M | $110M | $114.29M | $128.87M | $122.03M | $120.22M | $130.07M | $135.26M |
| PALYNZIQ | $90.63M | $100.41M | $93.27M | $105.94M | $108.78M | $125.33M | $89.56M | $135.17M |
| GALAFOLD | — | — | — | — | — | — | — | $105.75M |
| BRINEURA | $37.01M | $47.72M | $40.36M | $48.69M | $47.95M | $49.39M | $47.1M | $51.37M |
| ALDURAZYME | $71.03M | $39.04M | $48.98M | $56.44M | $53.71M | $49.39M | $36.74M | $43.54M |
| POMBILITI + OPFOLDA | — | — | — | — | — | — | — | $30.26M |
| KUVAN | $28.12M | $28.33M | $25.14M | $27.03M | $24.03M | $23.34M | $23.88M | $24.44M |
| ROCTAVIAN | $7.24M | $10.55M | $10.51M | $9.2M | $3.18M | $12.75M | $2.64M | $11.71M |
| Royalty and other revenues | $11.87M | $11.68M | $10.5M | $12.43M | $15.32M | $15.24M | $6.13M | $5.32M |
| Total | $745.74M | $747.31M | $745.15M | $825.41M | $776.13M | $874.57M | $766.21M | $989.71M |